A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 02 Oct 2019 Planned initiation date changed from 1 Sep 2019 to 1 Oct 2019.
- 20 Aug 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 2019 to 1 Sep 2019.
- 10 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2019 to 1 Jul 2019.